All sensitivity analyses (i.e., using a strict definition [stable use] for previous or current users of GLP-1RAs or SGLT2is, excluding the TZD effect, using the lag-time approach, and refining the treatment exposure period as 2 years before the index date) yielded results that are consistent with the primary findings, showing a decreased but insignificant risk of NAFLD/NASH events with the use of GLP-1RAs or SGLT-2is (Fig
Gholam, who is herself taking Ozempic, says she has become more thoughtful about her diet since taking the drug, and is eating smaller portions, more high-protein low-fat/sugar dairy products such as cottage cheese and skyr, more produce, and fewer empty carbs
273279, journals.lww.com/co-endocrinology/fulltext/2023/12000/glucagon_like_peptide_1_receptor_agonists_and.2.aspx, Purwar, Ananya, and Shailesh Nagpure
But additional mice experiments showed glucagon has an effect of increasing energy expenditure, which leads to weight loss